The present invention relates to a non-agonist ligand specifically binding to VCAM1 (CD106), CD49d, CD29, the IL6 receptor (CD126), IL6, the IL1β receptor (IL1R1), IL1β, F11R, ICAM1, or ITGB2 for use in treatment or prevention of metastatic cancer. The method further relates to a method for assigning a likelihood of developing metastasis to a patient.